Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries

Abstract Background Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated...

Full description

Bibliographic Details
Main Authors: Toby M. Maher, Maria Molina-Molina, Anne-Marie Russell, Francesco Bonella, Stéphane Jouneau, Elena Ripamonti, Judit Axmann, Carlo Vancheri
Format: Article
Language:English
Published: BMC 2017-09-01
Series:BMC Pulmonary Medicine
Subjects:
Antifibrotics
Idiopathic pulmonary fibrosis
Questionnaire
Treatment patterns
Unmet needs
Online Access:http://link.springer.com/article/10.1186/s12890-017-0468-5

Internet

http://link.springer.com/article/10.1186/s12890-017-0468-5

Similar Items